Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Sell
25
AARD Quote, Financials, Valuation and Earnings
Last price:
$7.06
Seasonality move
:
--
Day range:
$6.99 - $7.36
52-week range:
$4.88 - $19.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
30.4K
Avg. volume:
138.7K
1-year change:
--
Market cap:
$154.9M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
-- | -$0.71 | -- | -278.4% | $31.50 |
|
BMEA
Biomea Fusion
|
-- | -$0.60 | -- | -46.94% | $23.25 |
|
GEHC
GE HealthCare Technologies
|
$4.7B | $0.91 | 0.19% | 12.73% | $100.23 |
|
LLY
Eli Lilly and
|
$12.8B | $4.70 | 26.52% | 68.89% | $1,010.63 |
|
PLRX
Pliant Therapeutics
|
-- | -$0.75 | 61.11% | -1.32% | $10.06 |
|
SLNO
Soleno Therapeutics
|
-- | -- | -- | -- | $102.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
$7.14 | $31.50 | $154.9M | -- | $0.00 | 0% | -- |
|
BMEA
Biomea Fusion
|
$1.75 | $23.25 | $65.8M | -- | $0.00 | 0% | -- |
|
GEHC
GE HealthCare Technologies
|
$62.81 | $100.23 | $28.7B | 14.51x | $0.04 | 0.2% | 1.47x |
|
LLY
Eli Lilly and
|
$732.41 | $1,010.63 | $657.8B | 62.55x | $1.50 | 0.74% | 14.70x |
|
PLRX
Pliant Therapeutics
|
$1.34 | $10.06 | $82.1M | -- | $0.00 | 0% | 16.14x |
|
SLNO
Soleno Therapeutics
|
$67.23 | $102.13 | $3.1B | -- | $0.00 | 0% | 3,450.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
-- | 0.000 | -- | -- |
|
BMEA
Biomea Fusion
|
-- | 2.580 | -- | -- |
|
GEHC
GE HealthCare Technologies
|
51.45% | 1.336 | 24.91% | 0.76x |
|
LLY
Eli Lilly and
|
70.33% | 0.800 | 5.05% | 0.59x |
|
PLRX
Pliant Therapeutics
|
-- | 3.584 | -- | -- |
|
SLNO
Soleno Therapeutics
|
-- | -2.069 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
BMEA
Biomea Fusion
|
-- | -$34M | -- | -- | -- | -$25.4M |
|
GEHC
GE HealthCare Technologies
|
$2.3B | $801M | 11.43% | 24.88% | 17.77% | $811M |
|
LLY
Eli Lilly and
|
$11.1B | $5.8B | 25.09% | 80.24% | 38.89% | $726.6M |
|
PLRX
Pliant Therapeutics
|
-- | -$53.3M | -- | -- | -- | -$47.9M |
|
SLNO
Soleno Therapeutics
|
-- | -$58.8M | -- | -- | -- | -$24M |
Aardvark Therapeutics vs. Competitors
-
Which has Higher Returns AARD or BMEA?
Biomea Fusion has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Biomea Fusion's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- BMEABiomea Fusion-- -$0.91 -- -
What do Analysts Say About AARD or BMEA?
Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 341.18%. On the other hand Biomea Fusion has an analysts' consensus of $23.25 which suggests that it could grow by 1228.57%. Given that Biomea Fusion has higher upside potential than Aardvark Therapeutics, analysts believe Biomea Fusion is more attractive than Aardvark Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 BMEABiomea Fusion4 2 0 -
Is AARD or BMEA More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biomea Fusion has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AARD or BMEA?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomea Fusion offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Biomea Fusion pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or BMEA?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Biomea Fusion quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Biomea Fusion's net income of -$32.8M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Biomea Fusion's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus -- for Biomea Fusion. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- BMEABiomea Fusion-- -- -- -$32.8M
-
Which has Higher Returns AARD or GEHC?
GE HealthCare Technologies has a net margin of -- compared to Aardvark Therapeutics's net margin of 13.56%. Aardvark Therapeutics's return on equity of -- beat GE HealthCare Technologies's return on equity of 24.88%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- GEHCGE HealthCare Technologies42.77% $1.57 $17.6B -
What do Analysts Say About AARD or GEHC?
Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 341.18%. On the other hand GE HealthCare Technologies has an analysts' consensus of $100.23 which suggests that it could grow by 59.57%. Given that Aardvark Therapeutics has higher upside potential than GE HealthCare Technologies, analysts believe Aardvark Therapeutics is more attractive than GE HealthCare Technologies.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 GEHCGE HealthCare Technologies12 4 1 -
Is AARD or GEHC More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GE HealthCare Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AARD or GEHC?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GE HealthCare Technologies offers a yield of 0.2% to investors and pays a quarterly dividend of $0.04 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. GE HealthCare Technologies pays out 2.76% of its earnings as a dividend. GE HealthCare Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AARD or GEHC?
Aardvark Therapeutics quarterly revenues are --, which are smaller than GE HealthCare Technologies quarterly revenues of $5.3B. Aardvark Therapeutics's net income of -- is lower than GE HealthCare Technologies's net income of $721M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while GE HealthCare Technologies's PE ratio is 14.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 1.47x for GE HealthCare Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- GEHCGE HealthCare Technologies1.47x 14.51x $5.3B $721M
-
Which has Higher Returns AARD or LLY?
Eli Lilly and has a net margin of -- compared to Aardvark Therapeutics's net margin of 32.59%. Aardvark Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- LLYEli Lilly and82.24% $4.88 $47.9B -
What do Analysts Say About AARD or LLY?
Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 341.18%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.63 which suggests that it could grow by 37.99%. Given that Aardvark Therapeutics has higher upside potential than Eli Lilly and, analysts believe Aardvark Therapeutics is more attractive than Eli Lilly and.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 LLYEli Lilly and16 4 0 -
Is AARD or LLY More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.
-
Which is a Better Dividend Stock AARD or LLY?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AARD or LLY?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Aardvark Therapeutics's net income of -- is lower than Eli Lilly and's net income of $4.4B. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 62.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 14.70x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- LLYEli Lilly and14.70x 62.55x $13.5B $4.4B
-
Which has Higher Returns AARD or PLRX?
Pliant Therapeutics has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Pliant Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- PLRXPliant Therapeutics-- -$0.82 -- -
What do Analysts Say About AARD or PLRX?
Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 341.18%. On the other hand Pliant Therapeutics has an analysts' consensus of $10.06 which suggests that it could grow by 650.93%. Given that Pliant Therapeutics has higher upside potential than Aardvark Therapeutics, analysts believe Pliant Therapeutics is more attractive than Aardvark Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 PLRXPliant Therapeutics1 11 0 -
Is AARD or PLRX More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pliant Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AARD or PLRX?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pliant Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Pliant Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or PLRX?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Pliant Therapeutics quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Pliant Therapeutics's net income of -$49.7M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Pliant Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 16.14x for Pliant Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- PLRXPliant Therapeutics16.14x -- -- -$49.7M
-
Which has Higher Returns AARD or SLNO?
Soleno Therapeutics has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Soleno Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- SLNOSoleno Therapeutics-- -$1.27 -- -
What do Analysts Say About AARD or SLNO?
Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 341.18%. On the other hand Soleno Therapeutics has an analysts' consensus of $102.13 which suggests that it could grow by 51.9%. Given that Aardvark Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Aardvark Therapeutics is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 SLNOSoleno Therapeutics5 0 0 -
Is AARD or SLNO More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics has a beta of -2.285, suggesting its less volatile than the S&P 500 by 328.466%.
-
Which is a Better Dividend Stock AARD or SLNO?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Soleno Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or SLNO?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Soleno Therapeutics quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Soleno Therapeutics's net income of -$56M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Soleno Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 3,450.85x for Soleno Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- SLNOSoleno Therapeutics3,450.85x -- -- -$56M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
